Freedom Investing Report
  • Sports
  • Politics
  • Stocks
  • Business
  • Sports
  • Politics
  • Stocks
  • Business

Freedom Investing Report

Sports

Braves player hit with 162-game ban after second PED violation

by March 4, 2026
March 4, 2026
Braves player hit with 162-game ban after second PED violation

Jurickson Profar upended his career and the Atlanta Braves’ season for a second consecutive year after testing positive for a banned substance, a second offense that will result in a 162-game ban for the 2026 season, Major League Baseball announced March 3.

Profar tested positive for exogenous testosterone, MLB said, a performance-enhancing substance banned from Olympic competition since 1976 and classified as a steroid in the U.S. since 1990, according to the National Institutes of Health.

Profar, 33, was entering the first season of a three-year, $42 million contract when he was suspended March 31, 2025, just four games into last season, after a positive test for a fertility drug classified as a performing-enhancing substance. He was suspended 80 games and returned July 2, hitting 14 homers with a .787 OPS over the remaining 80 games.

This suspension will be far more costly.

Profar will lose his entire 2026 salary of $15 million, bringing his docked pay for his two positive tests to around $21 million over two seasons. He’s also ineligible to represent the Netherlands in the upcoming World Baseball Classic.

Profar was entering his 13th major league season after debuting as a 19-year-old in 2012. He earned his first All-Star appearance in 2024 for the San Diego Padres, establishing career bests in home runs (24) and OPS (.839), prompting the Braves to sign him as their left fielder entering 2025.

Now, he won’t be seen on the Truist Field diamond until 2027.

Profar joins five other players to earn at least a 162-game ban under MLB’s policy, most notably Robinson Cano, who earned two suspensions amid a $240 million contract he originally signed with Seattle, the bans sidetracking what looked like a Hall of Fame career.

For the Braves, the timing is certainly suboptimal though not as bad as last season, when the season had started and they scrambled to fill Profar’s absence, eventually signing free agent Alex Verdugo. This year, they can roll out Mike Yastrzemski in an enhanced role, but Profar’s absence will hamper their depth significantly.

This post appeared first on USA TODAY
previous post
Free agent Trey Hendrickson says goodbye to Cincinnati Bengals
next post
College baseball game briefly paused after pelican gets stuck in net

Related Posts

Trey Lance’s bro won’t be drafted as early...

February 28, 2026

Chase Pistone, former NASCAR driver, dies at 42

March 3, 2026

Trinity Rodman ‘fine’ after back injury scare, says...

March 3, 2026

Team USA stars ready to win WBC for...

March 2, 2026

FIFA president still wants Iran to play in...

March 3, 2026

Former LSU star makes case for QB2 in...

March 2, 2026

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Sports (168)
    • About Us
    • Contacts
    • Terms & Conditions
    • Privacy Policy
    • Email Whitelisting

    Disclaimer: FreedomInvestingReport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023 FreedomInvestingReport.com | All Rights Reserved